Introduction
Glatiramer acetate (GA) has been shown to reduce both the relapse rate and the appearance of new central nervous system (CNS) lesions in multiple sclerosis (MS) [1, 2] . GA is a polymer of the four amino acids most prevalent in myelin basic protein (MBP) and has been shown to bind several different human leukocyte antigen (HLA)-DR molecules [3] . Antigen presenting cells (APCs) within or outside the CNS may be the primary target of GAmediated immune modulation [4] [5] [6] . The mechanism of GA is thought to involve induction of anti-inflammatory GA-reactive T cells in secondary lymphoid organs [7] . Anergy induction of activated and potentially pathogenic T cells is thought to play a role as long-term GA treatment leads to a drop in the precursor frequency of GA-reactive T cells [8, 9] . Within the CNS, GA-reactive T cells may cross-react with myelin proteins [10] [11] [12] , dampen the inflammatory response by secretion of anti-inflammatory Th2 cytokines such as interleu-kin (IL)-4, IL-5, IL-10, and IL-13, [10, 13, 14] , induce regulatory T cells [5] , and stimulate reparative processes through secretion of neurotrophic factors [15] [16] [17] [18] .
For these mechanisms to be relevant in MS, GAreactive T cells must gain access to the CNS. Studies in mice have shown that GA-reactive T cells induced in the periphery penetrate the blood-brain barrier [13, 14] , and human GA-reactive T cells have been shown to migrate across an artificial bloodbrain barrier in vitro [19] . However, because of difficulties in investigating migration of human T cells in vivo, current knowledge of human GA-reactive T cells stems from analyses conducted with lymphocytes derived from blood.
Studies in MS and other immune-mediated diseases have shown that T cells from the diseased organ may differ from T cells in blood [20] [21] [22] [23] . To understand the effects of GA in MS, it is therefore important to investigate GA-reactive T cells from the intrathecal compartment. The aim of the present study was to compare GA-reactive T cells from blood and cerebrospinal fluid (CSF) in terms of cytokine profile, HLA restriction, and crossrecognition properties before and after initiation of GA treatment.
Materials and methods

Patients
Five patients (four women and one man) with relapsing-remitting MS (Expanded Disability Status Scale 1-2) gave informed consent to participate in this study. Study participants were treated by neurologists with no other involvement in the study and had received 20 mg GA daily for 0-36 months at inclusion. The study was approved by the local ethics committee.
Antigens
GA (copaxone © ) was obtained from Teva Pharmaceuticals Ltd (London, UK). In all, 531 15-mer peptides, overlapping by 10 amino acids spanning the complete sequences of MBP (18.5 kDa and 21.5 kDa isoforms), protelipid protein (PLP), myelinoligodendrocyte glycoprotein (MOG; including the β2 isoform), myelin-associated oligodendrocytic basic protein, myelin-associated glycoprotein, oligodendrocyte myelin glycoprotein, αβ-crystallin, S100β, and 2′, 3′-cyclic nucleotide 3'phosphodiesterase (partly a gift from N. Karandikar, UT Southwestern Medical Center, Dallas, Texas, USA) were synthesized using standard techniques (BioSynthesis, Texas, USA) at 44.8-100% purity (0.5% were below 50% pure and 12% were above 90% pure) [24] . Peptides were dissolved in dimethyl sulfoxide (DMSC) at a concentration of 50 mg/mL and tested in pools of 8-10 peptides; each peptide was tested at a concentration of 2.5 μM. A chymotrypsin digest of gluten extracted from wheat flour (gift from O. Molberg, Institute of Immunology, Rikshospitalet Radiumhospitalet, Oslo, Norway), human MBP (Chemicon, California, USA), and a peptide from glutamic acid decarboxylase (GAD 57-72 ) served as control antigens.
Generation of T cell lines and T cell clones
In all, 40,000-160,000 cells were obtained from 23 mL CSF collected by lumbar puncture. No bleeding was observed during the procedures. To further avoid blood contamination, the first 2 mL of CSF were discharged. To minimize differences related to in vitro conditions, T cell lines from CSF and blood were cultured in parallel using identical pro-cedures. Briefly, 1 × 10 5 peripheral blood mononuclear cells (PBMC) or 4000-6000 CSF cells were incubated with 10 5 irradiated (25 Gy) autologous PBMC, which had been pre-incubated overnight with 50 or 200 μg/mL GA. Cells were stimulated with 10 IU/mL IL-2 (RnDSystems, Minnesota, USA) on day 7 and restimulated on day 14 with 10 5 irradiated autologous PBMC and 50 or 200 μg/mL GA. The T cell lines were expanded with irradiated heterologous PBMC, 1 μg/mL phytohemagglutinin (Remel, Kansas, USA), and 10 IU/mL IL-2 on day 20 and tested for specificity and cytokine production on day 28 with autologous PBMC preincubated overnight with 50 or 200 μg/mL GA. T cell cloning and determination of the HLA-isotype presenting GA were performed using procedures and monoclonal antibodies described previously [25] .
Proliferation assays T cells were tested by incubating 10 5 T cells suspended in 200 μL medium with 10 5 irradiated autologous PBMC, which had been pre-incubated with antigen overnight in 100 μL medium. T cells were cultured for 72 h and proliferation tested on the basis of 3 H-thymidine incorporation as described previously [25] . A proliferative response was scored as positive if counts per minute (cpm) of stimulated wells minus cpm of unstimulated wells (Δcpm) exceeded 1000 and the stimulatory index (SI) exceeded 3 [23] .
Cytokine measurement
Supernatants of T cells were frozen at −80°C for 48 h after antigen stimulation. Concentrations of IL-4, IL-5, IL-10, IL-13, IL-17, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ were measured with a custom-made multiplex antibody bead kit (Biosource International Inc., Camarillo, California, USA) for Luminex™, according to the manufacturer's recommendations. The detection level for all cytokines was 3-5 pg/mL. Unstimulated T cells incubated with irradiated PBMC in the absence of antigen served as control. Irradiated PBMC incubated with antigen overnight produced no detectable levels of the cytokines. Cytokine production was calculated as cytokine concentrations in supernatants from antigen-stimulated cells (T + APC + GA) minus unstimulated cells (T + APC).
Statistics
Cytokine ratios were compared with a two-way ANOVA analysis with patients as random effect in Statistical Package for the Social Sciences (SPS) version 15 (SPSS Inc., Chicago, Illinois, USA). To correct for deviation from the normal distribution, data were log transformed before analysis. The proportion of Th1-biased and Th2-biased GA-reactive T cell lines was analyzed using generalized estimating equation regression models in Statistical Analysis System (SAS) version 9.1 (SAS Inc., Cary, North Carolina, USA).
Results
GA-reactive T cells are present in the CSF and blood before and during GA treatment
To establish whether GA-reactive T cells are present in the CSF of patients before and after initiation of treatment, 22 T cell lines from CSF and 36 T cell lines from blood were generated from patients 1-3 before they started GA treatment, and 28 T cell lines from CSF and 31 T cell lines from blood of the same patients were generated after 3-6 months on treatment. All T cell lines generated both before and during treatment from both blood and CSF responded vigorously to GA both by proliferation and cytokine production ( Figure 1 ). Although the number of CSF cells is too low to allow calculation of the frequency of GA-specific T cells, the observation that all T cell lines were GA-reactive indicates that the precursor frequency of GA-specific T cells in CSF both before and after initiation of GA treatment exceeds 1:5000.
Th2-bias is more pronounced in GA-reactive T cell lines from CSF than from blood
To establish cytokine profiles of GA-reactive T cells, concentrations of pro-and anti-inflammatory cytokines were measured in supernatants of proliferating GA-reactive T cell lines. Using an IL-5/IFN-γ ratio of 1 as the cut-off between a predominant Th1 versus Th2 phenotype, 13 of 22 GA-reactive T cell lines from CSF and 11 of 36 GA-reactive T cell lines from blood were Th2-biased before treatment. After treatment, the proportion of predominantly Th2-biased GA reactive T cell lines from the same patients was 25 of 28 (CSF) and 21 of 31 (blood). Thus, short-term GA-treatment induced an increase in the ratio of Th2-biased cell lines in both CSF and blood. The increase was only Figure 1 Glatiramer acetate (GA)-reactive T cell lines (TCL) can be generated from the CSF of GA-treated and treatment naive individuals. Proliferative responses (Δcpm) against four-fold serial dilutions of GA from 800-0.2 μg/mL GA in three representative CSF T cell lines from patient 1 generated before GA-treatment (CSF TCL 1-3) and after 3 months on GA treatment (CSF TCL 4-6) are shown (A). None of the T cell lines displayed any proliferation in response to 20-0.003 μg/mL myelin basic protein or gluten in the same experiment (data not shown). Production of IL-5 and IFN-γ is shown for all cell lines (B). significant in the CSF (P = 0.03), where a shift towards almost total dominance of Th2-biased GAreactive T cells was observed.
No consensus exists regarding the threshold ratios that define human T cells as Th1 or Th2. In addition to comparisons based on a potentially arbitrary classification into Th1-biased and Th2-biased T cell lines it is therefore also important to compare absolute ratios of pro-and anti-inflammatory cytokines produced by GA-reactive T cell lines from blood and CSF before and during GA treatment. Figure 2 depicts the secretion of IL-5, IL-10, and IL-13 compared with IFN-γ produced by GA-reactive T cell lines before and during treatment for patients 1-3. Results for the secretion of IL-5, IL-10, and IL-13 compared with IFN-γ and TNF-α in patients 1-3 combined are given in Figure 3 . These results show that i) in T cells from CSF, GA treatment induced a highly significant increase in the secretion of IL-5, IL-10, and IL-13 compared with IFN-γ and TNF-α; ii) in T cells from blood, GA-treatment induced a highly significant increase in the secretion of IL-5, IL-10, and IL-13 compared with IFN-γ but not compared with TNF-α; iii) after 3-6 months on GA treatment, there is a prominent and significant Th2-polarization of GA-reactive T cells from both CSF and blood, Figure 2 Short-term glatiramer acetate (GA) treatment induces a Th2-bias of GA-reactive T cells, which is most prominent in CSF. Each data point represents the indicated cytokine ratio for individual GA-reactive T cell lines before and after 3 months (patient 1) or 6 months (patient 2 and 3) of treatment.
which is more pronounced in T cells from CSF. The Th2-polarization of GA-reactive T cells was evident in each of the three patients.
IL-17 has recently been identified as an important pro-inflammatory cytokine [26] . In CSF, IL-17 production was detected in 5 of 21 GA-reactive T cell lines during GA treatment compared with 10 of 28 before treatment. In blood, IL-17 production was detected in 11 of 31 GA-reactive T cell lines during GA treatment compared with 18 of 37 before treatment. These differences were not significant (results not shown).
Patients 1-3 had only received GA for 3-6 months. To assess the impact of prolonged treatment, we established 10 GA-reactive T cell lines from CSF and 23 GAreactive T cell lines from blood obtained from two patients who had received GA for 24 and 36 months (patients 4 and 5). Interestingly, GA-reactive T cell lines from both CSF and blood of these patients displayed a significantly stronger Th2-bias than GAreactive T cells from the short-term treated patients ( Figure 4a ). Although based on few patients, these results suggest that long-term treatment further enhances the Th2-polarization of GA-reactive T cells, which is most pronounced in CSF.
Combining results for all GA-reactive T cell lines generated after initiation of GA treatment from patients 1-5 further confirms that GA-reactive T cells from CSF display a more pronounced antiinflammatory profile than GA-reactive T cells from the blood (Figure 4b ). In sum, the mean IL-5/IFN-γ ratio of GA-reactive T cells from CSF was 35.8 (95% CI: 20.4-51.6), compared with 9.6 (95% CI: 6.3-12.8) for GA-reactive T cells from blood (P < 0.005).
GA-specific T cells from CSF are restricted by either HLA-DR or HLA-DP
To investigate the characteristics of individual GAspecific T cells, we cloned GA-reactive T cell lines from patients 4 and 5 by limiting dilution. The cloning frequency was less than 5% making it more than 95% probable that each cell culture was monoclonal [27] . Forty-eight of 90 T cell clones from patient 4 and 154 of 379 T cell clones from patient 5 specifically recognized GA (mean Δcpm = 130239 and mean SI = 341 for 20 tested clones). Proliferative responses of representative T cell clones with and without HLA-blocking antibodies and HLA restriction are shown in Figure 5 . Interestingly, all 10 tested T cell clones from blood were restricted by HLA-DR, whereas HLA-DP restricted T cells were cloned from CSF of both patients. One of five CSF T cell clones from patient 4 and three of five CSF T cell clones from patient 5 were restricted by HLA-DP.
Cross-reactivity with myelin proteins
GA-reactive T cells from mice and human blood have been reported to cross-recognize GA and myelin proteins, especially MBP [10, 12, 28, 29] . To our knowledge, cross-reactivity in human T cells has not been confirmed at a clonal level. To investigate whether cross-reactivity can be detected at a clonal level, 20 GA-specific T cell clones (10 from CSF and 10 from blood) from patient 4 and 5 were tested for proliferation against 531 peptides spanning most myelin proteins suggested to be associated with MS [30] and for cytokine production against 146 peptides spanning MBP, MOG, and PLP. Because all T cell lines previously had produced either IFN-γ or IL-5 in response to GA, these two cytokines were used to assess cross-reactivity at the cytokine level.
None of the 20 T cell clones showed any signs of proliferation or cytokine production in response to the peptide library. The T cells responded vigorously to GA in the same experiment (mean Δcpm: 64,098; mean IFN-γ concentration 3400 pg/mL and mean IL-5 concentration 2330 pg/mL). The T cell clones were also tested against complete MBP. MBP did not elicit any proliferation, but we were able to detect a small amount of IFN-γ production in one T cell clone from blood (10 pg/mL elicited by MBP versus 350 pg/mL elicited by GA). MBP did not elicit any detectable cytokine production in T cell clones from CSF.
GA-reactive T cell clones may represent a biased subpopulation of the total GA-reactive T cell repertoire. To test if cross-reactive T cells were represented in the polyclonal GA-reactive T cell lines, all 117 GA-reactive T cell lines from patients 1-3 were tested for cross-reactivity against complete MBP. Neither MPB nor the control protein (gluten) elicited any detectable proliferation or cytokine production. The T cells responded vigorously to GA in the same experiment (mean IL-5 concentration 3900 pg/mL; mean IFN-γ concentration 1880 pg/mL; mean Δcpm > 100,000).
Discussion
In the current study, we examined GA-reactive T cells from the CSF of humans and provided longitudinal information about the intrathecal immune response against GA at the clonal level. The principal findings are that (i) GA-reactive T cells are present in the intrathecal compartment of MS patients Figure 4 Glatiramer acetate (GA)-reactive T cell lines from patients treated long-term (patients 4 and 5) display more pronounced Th2-bias than GA-reactive T cell lines from patients treated short-term (patients 1-3) with GA (A). Following 3-36 months of GA treatment, GA-reactive T cells from the CSF of patients 1-5 display a more pronounced Th2-bias than T cells from blood (B). Concentrations of cytokines were measured in supernatants of proliferating GA-reactive T cell lines 48 h after stimulation with GA. Each data point represents the IL-5/IFN-γ ratio for one cell line. *P < 0.05; **P < 0.01; ***P < 0.005. The absolute IFN-γ and IL-5 concentrations (pg/mL, mean/SD) for all CSF and blood T cell lines from patient 4 and 5 were 800, 1253 and 5361, 1874, respectively (For patients 1-3, see legend Figure 3 ). before and after initiation of GA-treatment; (ii) GA treatment induces a Th2-bias of GA-reactive T cells from CSF and blood; and iii) following treatment, the Th2-bias is more pronounced in GA-reactive T cells from CSF than from blood. These results support an anti-inflammatory T cell-mediated mechanism of action for GA. Resting T cells are not able to penetrate the intact blood-brain barrier, whereas activated T cells seem to gain access to the CNS regardless of their specificity [31] . The finding that GA-reactive T cells were present in the CSF before treatment, therefore, suggests that some GA-reactive T cells exist in an activated state in the absence of treatment. Accordingly, previous studies have shown high frequencies of GA-reactive memory T cells in the blood of treatment-naive individuals [32, 11] .
GA is quickly degraded upon subcutaneous administration, making it unlikely that GA reaches the CNS in sufficient concentrations to induce Th2polarization within the CNS [33] . Although GA-reactive T cells were present in the CSF before treatment, the observation that GA treatment induced an increasing Th2-polarization in both CSF and blood is compatible with the notion that a Th2shift is induced in the periphery, and that a subpopulation of GA-reactive T cells subsequently gains access to the CNS. An alternative or additional explanation is the migration of type II monocytes to the CNS and induction of Th2 T cells at the site of inflammation [5, 6] . The Th2-shift in blood of the short-term treated patients may be less pronounced than previously observed in long-term treated patients [12] , and it is therefore possible that the more pronounced Th2 induction observed in CSF is a transient phenomenon. However, the marked Th2-bias in CSF compared with blood in the two long-term treated patients suggests that there is a persistent difference in favor of a more pronounced Th2-bias in CSF compared with blood.
Several observations suggest that intrathecal GA-reactive T cells are not a random selection of Figure 5A . Figure 5B shows proliferative responses to GA (in cpm) of the same T cell clones with or without monoclonal antibodies against HLA-DR, -DQ, -DP and HLA class I. Medium control represents T cells and antigen-presenting cells in the absence of GA.
GA-reactive T cells from blood. First, GA-reactive T cells from CSF were more Th2-biased than GA-reactive T cells from blood, possibly reflecting that GA induces Th2-skewing earlier in CSF than in blood or a preferential migration of strongly Th2-biased T cells to the CSF. Second, GA treatment imposed a more pronounced reduction in TNF-α secretion in GA-reactive T cells from CSF than from blood. Third, GA-specific T cells from the CSF were restricted by either HLA-DP or HLA-DR, whereas only HLA-DR restricted T cells were detected in blood. HLA restriction of GA-specific T cells from blood has previously been extensively studied, and HLA-DP restriction has to our knowledge not been reported [3, 34] . The finding of HLA-DP restricted GA-reactive T cells in CSF was, therefore, highly unexpected and supports that a subset of GA-reactive T cells selectively accesses the intrathecal compartment.
In this study, we only detected GA-reactive CD4 + T cells. GA may also have an effect on CD8 + T cells as shown by clonal expansion of GA-reactive CD8 + T cells from the blood of patients receiving GA [35] . This difference may be related to different methodological approaches. There are few reports on cloned GA-specific T cells [34] and to our knowledge no GA-specific CD8 + T cell clones have been established. The method applied in this study has previously allowed generation of T cell lines and clones with several specificities from the limited number of CD4 + T cells in CSF of MS patients [22, 36] , but there is currently no adequate method to establish antigen specific CD8 + T cell lines and clones from CSF and we can, therefore, not exclude that CD8 + GA-reactive T cells are present in the intrathecal compartment.
The dissimilarities between GA-reactive T cells from CSF and blood can hardly be explained by differences in APCs or other in vitro factors because identical procedures were used to generate T cells from both compartments. The mechanisms recruiting a particular subset of GA-reactive T cells to the CSF are not clear, but several possibilities exist. Restimulation of GA-reactive T cells by crossrecognition of myelin antigens within the CNS could explain expansion of a particular subset of GA-reactive T cells within the CNS [13] . However, GA-reactive T cells from blood and CSF in this study displayed almost no cross-reactivity. Previous studies have shown that a proportion of human GA-reactive T cell lines from blood cross-recognize MBP [11, 32] . Moreover, GA treatment has been found to induce degenerated T cell responses with broad cross-reactivity, suggesting that crossrecognition might also occur outside the CNS [12] . Cross-recognition of myelin proteins can, therefore, hardly explain the differences between GA-reactive T cells from CSF and blood. Another possibility is that a selected subpopulation of GA-reactive T cells penetrates the blood-brain barrier. T cells from CSF display a more activated phenotype than T cells from blood [20, 23] , and differences in cytokine profiles could reflect differences in activation status. However, a putative difference in activation status between GA-reactive T cells in blood and CSF would be expected to decline during prolonged treatment and could hardly explain the selective finding of HLA-DP restricted T cells in CSF. Further studies of expression of chemokine receptors and adhesion molecules on T cells from blood and CSF may contribute to our understanding of these intriguing findings. The expression patterns of such molecules are, however, sensitive to in vitro changes during cell culture and are difficult to establish directly ex vivo with the limited numbers of T cells available from CSF.
Several studies on T cells from mice and human blood have shown cross-reactivity between GA and MBP. In one study, some GA-reactive T cell lines proliferated vigorously against MBP [32] . In other studies, evidence of cross-reactivity has been absent or limited to cytokine secretion [10, 12, 28, 29, 37] . In this study, we primarily studied cross-reactivity between GA and myelin proteins at a clonal level, whereas previous studies have studied polyclonal T cell lines [11, 12] . The strict approach adopted here may have contributed to the finding of very limited cross-reactivity in this study. By definition, cross-reactivity of T cells means that one T cell receptor recognizes two different antigens and must, therefore, be established at a clonal level [38, 39] . Because of limited cell numbers, it was only possible to test the extensive panel of myelin protein peptides at one concentration, and crossreactivity between GA and myelin protein peptides with low affinity for the relevant HLA molecule or GA-reactive T cell receptor can, therefore, not be excluded. It must, however, be kept in mind that only 10-17% of polyclonal GA-reactive T cell lines from MS patients cross-recognized MBP in previous studies [11, 32] . The limited finding of crossreactivity at the clonal level in this study was, therefore, not unexpected and agrees with recent findings showing that cross-reactivity of adoptively transferred T cells from GA-treated mice was not necessary for the therapeutic benefit in recipient mice [5] . These findings support previous suggestions that GA may also be effective in inflammatory diseases outside the CNS [40, 41] .
In summary, our data support an antiinflammatory mechanism of action for GA at the site of the pathogenic process in MS and highlight the need to study intrathecal T cells in MS patients.
